NVRO - Nevro Corp.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 26.45 |
| Open | 26.18 |
| Bid | 25.24 x 1000 |
| Ask | 26.18 x 1000 |
| Day's Range | 25.98 - 26.65 |
| 52 Week Range | 25.82 - 53.34 |
| Volume | |
| Avg. Volume | 554,085 |
| Market Cap | 932.68M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 325.50 |
| EPS (TTM) | 0.08 |
| Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 41.86 |
Fair Value
Related Research
PR NewswireNevro to Present at Jefferies Healthcare Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal, Nevro's CEO and President, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 10:30 am Eastern Time at the Marriott Marquis Hotel in New York, NY.
Simply Wall St.Nevro Corp.'s (NYSE:NVRO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Nevro Corp. ( NYSE:NVRO ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
- PR Newswire
Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced on April 24, 2023, the Board of Director of Nevro granted restricted stock unit awards covering an aggregate of 135,623 shares of its common stock (the RSU Award) and performance unit awards covering 135,623 shares of its common stock (the PSU Award and together, the Awards) to Kevin Thornal, who joined Nevro as its Chief Executive
ZacksNevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.
ZacksNevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2023 financial results. The company also provided second quarter guidance and reiterated its full-year 2023 guidance.
ZacksEcolab (ECL) to Report Q1 Earnings: What's in the Offing?
Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.
ZacksMedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
ZacksHow Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- PR Newswire
Nevro Announces Enrollment of First Patient in PDN Sensory Study
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has enrolled the first patient in its Painful Diabetic Neuropathy (PDN) Sensory Study, which is the first prospective randomized controlled trial (RCT) to assess restoration of neurological function as a primary objective in patients with intractable PDN. The study will enroll up to 236 patients at multiple sites across the
ZacksWill OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know
OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Nevro Announces Participation in Upcoming Investor Conferences
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:
Motley FoolWhy Nevro Stock Is Tanking Today
Shares of the medical device company Nevro (NYSE: NVRO) were down by an unsightly 18.9% on exceptionally heavy volume at 10:57 a.m. ET Thursday. The big loss came after the company announced that Kevin Thornal will take the reins as CEO and president following the upcoming retirement of current CEO/president D. Keith Grossman on April 24, 2023. In addition, Nevro announced preliminary, unaudited revenue for the first quarter of 2023 in the same press release.
PR NewswireNevro Names Kevin Thornal as New Chief Executive Officer and President
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that Kevin Thornal has been appointed Chief Executive Officer and President of Nevro, effective April 24, 2023, and will also be appointed to the Board of Directors. Mr. Thornal succeeds D. Keith Grossman, who is retiring as Chief Executive Officer and President, also effective April 24, 2023. Mr. Grossman will be appointed to serv
- Simply Wall St.
Strong week for Nevro (NYSE:NVRO) shareholders doesn't alleviate pain of three-year loss
Nevro Corp. ( NYSE:NVRO ) shareholders should be happy to see the share price up 23% in the last month. But over the...
- PR Newswire
Nevro to Report First Quarter 2023 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2023 after the market closes on April 26, 2023.
- Zacks
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.
PR NewswireNevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has now initiated the U.S. full market launch of its HFX iQ spinal cord stimulation (SCS) system, following the completion of a successful limited market release.
- PR Newswire
Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2023 Medtech Innovation Spotlight Call Series on Friday, March 24, 2023 at 2:00 pm Eastern Time.
- Simply Wall St.
Nevro Full Year 2022 Earnings: EPS Beats Expectations
Nevro ( NYSE:NVRO ) Full Year 2022 Results Key Financial Results Revenue: US$406.4m (up 5.0% from FY 2021). Net income...
- Zacks
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
BenzingaAnalyst Looks For Improvement Signs For Nevro's Core Market In 2023 After Mixed Q4 Earnings
Nevro Corp (NYSE: NVRO) reported Q4 FY22 sales of $113.8 million, up 11% Y/Y as reported and 12% constant currency, beating the consensus of $113.40 million. Painful diabetic neuropathy (PDN) indication sales of approximately $17.3 million grew 329%, bringing the first full-year sales to approximately $48.0 million. Q4 FY22 U.S. trial procedures increased by 9%, while U.S. PDN trial procedures grew to 20% of total U.S. trials in the quarter. Guidance: Nevro expects Q1 FY23 sales of $94-$96 milli
ZacksNevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results. The company also provided first quarter and complete full-year 2023 guidance.